3-(but-3-ynyl)-1,3-oxazolidin-2-one | 864755-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-(but-3-ynyl)-1,3-oxazolidin-2-one
• 英文别名: 3-but-3-ynyl-1,3-oxazolidine-2-one；3-but-3-ynyl-1,3-oxazolidin-2-one
• CAS: 864755-84-0
• 化学式: C₇H₉NO₂
• 分子量: 139.154
• InChiKey: RYLAZYLTMZVHST-UHFFFAOYSA-N

物化性质

• 沸点：
  319.4±25.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(but-3-ynyl)-1,3-oxazolidin-2-one 、 4-碘藜芦醚 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以80%的产率得到3-[4-(3,4-dimethoxyphenyl)but-3-ynyl]-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof

  摘要：

  HIV-1反转录酶的非核苷类抑制剂被描述。这些抑制剂可以作为治疗HIV感染的联合疗法的一部分使用。本文描述的化合物具有抗病毒效力。此外，本文描述的化合物具有代谢稳定性。本文还描述了制备HIV-1反转录酶非核苷类抑制剂的过程。

  公开号：

  US20080300288A1
• 作为产物：
  描述：

  2-唑烷酮 、 对甲苯磺酸 3-丁炔酯 在 四丁基溴化铵 potassium carbonate 作用下， 以 甲苯 为溶剂， 以83%的产率得到3-(but-3-ynyl)-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof

  摘要：

  HIV-1反转录酶的非核苷类抑制剂被描述。这些抑制剂可以作为治疗HIV感染的联合疗法的一部分使用。本文描述的化合物具有抗病毒效力。此外，本文描述的化合物具有代谢稳定性。本文还描述了制备HIV-1反转录酶非核苷类抑制剂的过程。

  公开号：

  US20080300288A1

文献信息

• Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors
  作者：Bo-Liang Deng、Yujie Zhao、Tracy L. Hartman、Karen Watson、Robert W. Buckheit Jr.、Christophe Pannecouque、Erik De Clercq、Mark Cushman

  DOI：10.1016/j.ejmech.2008.09.013

  日期：2009.3

  stable bioisosteres, compounds bearing benzo[d]isoxazole and oxazolidine-2-one rings were designed and evaluated as a new series of potent HIV-1 non-nucleoside reverse transcriptase inhibitors with anti-HIV activity. All of the resulting ADAMs were found to inhibit HIV-1 RT with poly(rC)·oligo(dG) as the template primer. The most promising compound in this series was ADAM 3, with EC50 values of 40 nM (vs

  为了继续用稳定的生物等排体取代链烯基二芳基碳酸铅的代谢不稳定的甲基酯（ADAM），设计了带有苯并[ d ]异恶唑和恶唑烷-2-酮环的化合物，并将其评估为一系列新的有效HIV-1非-具有抗HIV活性的核苷逆转录酶抑制剂。发现所有所得的ADAM均以poly（rC）·oligo（dG）为模板引物抑制HIV-1 RT。该系列中最有前途的化合物是ADAM 3，其EC 50值为40 nM（vs HIV-1 RF）和20 nM（vs HIV-1 IIIB）。化合物3还抑制HIV-1逆转录酶，IC 50为0.91μM。ADAM 4在CEM-SS细胞中具有0.6μM的抗病毒EC 50和51.4分钟的血浆半衰期。
• Synthesis, Anti-HIV Activity, and Metabolic Stability of New Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
  作者：Bo-Liang Deng、Tracy L. Hartman、Robert W. Buckheit,、Christophe Pannecouque、Erik De Clercq、Phillip E. Fanwick、Mark Cushman

  DOI：10.1021/jm050452s

  日期：2005.9.1

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) are part of the combination therapy currently used to treat HIV infection. Based on analogy with known HIV-1 NNRT inhibitors, 18 novel alkenyldiarylmethanes (ADAMs) containing 5-chloro-2-methoxyphenyl, 3-eyanophenyl, or 3-fluoro-5-trifluoromethylphenyl groups were synthesized and evaluated as HIV inhibitors. Their stabilities in rat plasma have also been investigated. Although introducing 5-chloro-2-methoxyphenyl or 3-fluoro-5-trifluoromethylphenyl groups into alkenyldiarylmethanes does not maintain the antiviral potency, the structural modification of alkenyldiarylmethanes with a 3-cyanophenyl substituent can be made without a large decrease in activity. The oxazolidinonyl group was introduced into the alkenyldiarylmethane framework and found to confer enhanced metabolic stability in rat plasma.
• Replacement of the Metabolically Labile Methyl Esters in the Alkenyldiarylmethane Series of Non-Nucleoside Reverse Transcriptase Inhibitors with Isoxazolone, Isoxazole, Oxazolone, or Cyano Substituents
  作者：Bo-Liang Deng、Tracy L. Hartman、Robert W. Buckheit,、Christophe Pannecouque、Erik De Clercq、Mark Cushman

  DOI：10.1021/jm060449o

  日期：2006.8.1

  The alkenyldiarylmethanes (ADAMs) are a unique class of non-nucleoside reverse transcriptase inhibitors that have potential value in the treatment of HIV/AIDS. However, the potential usefulness of the ADAMs is limited by the presence of metabolically labile methyl ester moieties. A series of novel ADAMs were therefore designed and synthesized in order to replace the metabolically labile methyl ester moieties of the existing ADAM lead compounds with hydrolytically stable, fused isoxazolone, isoxazole, oxazolone, or cyano substituents on the aromatic rings. The methyl ester and methoxy substituents on both of the aromatic rings in the parent compound 1 were successfully replaced with metabolically stable moieties with retention of anti-HIV activity and a general decrease in cytotoxicity.
• [EN] ALKENYLDIARYLMETHANES, FUSED ANALOGS AND SYNTHESES THEREOF<br/>[FR] ALCENYLDIARYLMETHANES, ANALOGUES FONDUS ET SYNTHESE
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2007005531A2

  公开（公告）日：2007-01-11

  [EN] Non-nucleoside inhibitors of HIV-I reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing Non-nucleoside inhibitors of HIV-I reverse transcriptase.
  [FR] L'invention concerne des inhibiteurs non nucléosidiques de la transcriptase inverse du VIH-I. Ces inhibiteurs peuvent être partiellement impliqués dans une polythérapie visant à traiter l'infection à VIH. Les composés de l'invention possèdent en outre un effet antiviral puissant, et se caractérisent par une stabilité métabolique. Par ailleurs, l'invention concerne des procédés de préparation de ces inhibiteurs non nucléosidiques de la transcriptase inverse du VIH-I.
• [EN] ALKENYLDIARYLMETHANES HAVING NITROGEN-CONTAINING CARBOXYLIC ACID DERIVATIVES<br/>[FR] ALCÉNYLDIARYLMÉTHANES PRÉSENTANT DES DÉRIVÉS D'ACIDE CARBOXYLIQUE CONTENANT DE L'AZOTE
  申请人：CUSHMAN MARK S

  公开号：WO2008119028A1

  公开（公告）日：2008-10-02

  [EN] Alkenydiarylmethane compounds are described. Such compounds are a class of non-nucleoside inhibitors of HIV-I reverse transcriptase, which may also be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing alkenydiarylmethane compounds.
  [FR] La présente invention concerne des composés alcényldiarylméthanes. Ces composés constituent une catégorie d'inhibiteurs non-nucléosides de la transcriptase inverse du VIH-I, qui peuvent également être utilisés dans le cadre d'une thérapie combinatoire visant à traiter une infection par le VIH. Les composés décrits ici présentent une activité antivirale. Ces composés possèdent en outre une stabilité métabolique. La présente invention concerne également des procédés de préparation de composés alcényldiarylméthanes.